Results 1 to 10 of about 252 (105)

Clinical Outcomes of MLC601 (NeuroAiD^TM) in Traumatic Brain Injury: A Pilot Study [PDF]

Brain Sciences, 2020
Background: MLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of ...
Asra Al Fauzi, Krisna Tsaniadi Prihastomo, I. G. M. Aswin R. Ranuh, Tedy Apriawan, Joni Wahyuhadi, M. Arifin Parenrengi, Agus Turchan, Abdul Hafid Bajamal, Hari Basuki Notobroto   +8 more
doaj   +15 more sources

MLC601 in vascular dementia: an efficacy and safety pilot study [PDF]

Neuropsychiatric Disease and Treatment, 2017
Hossein Pakdaman,1 Ali Amini Harandi,1 Koroush Gharagozli,1 Mehdi Abbasi,1 Majid Ghaffarpour,2 Farzad Ashrafi,1 Hosein Delavar Kasmaei,1 Asghar Amini Harandi3 1Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran ...
Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Ghaffarpour M, Ashrafi F, Delavar Kasmaei H, Amini Harandi A   +7 more
doaj   +7 more sources

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study [PDF]

Dementia and Geriatric Cognitive Disorders Extra, 2017
Background and Aim: Mild cognitive impairment (MCI) is characterized by declined cognitive function greater than that expected for a person’s age. The clinical significance of this condition is its possible progression to dementia.
Hossein Pakdaman, Ali Amini Harandi, Mehdi Abbasi, Hosein Delavar Kasmaei, Farzad Ashrafi, Koroush Gharagozli, Farhad Assarzadegan, Behdad Behnam, Mehran Arabahmadi   +8 more
doaj   +6 more sources

Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD [PDF]

Journal of Cardiovascular Development and Disease, 2023
Despite recent progress with revascularisation interventions after acute ischemic stroke, many patients remain disabled after stroke. Using data from a multi-centre, randomised, double-blind, placebo-controlled trial of a neuro-repair treatment (NeuroAiD/
Narayanaswamy Venketasubramanian, Yogesh Pokharkar, Jia Hui Chai, Christopher Li Hsian Chen   +3 more
doaj   +4 more sources

Cost-effectiveness of MLC601 in post-stroke functional recovery compared with placebo - the CHIMES & CHIMES-E studies [PDF]

BMC Health Services Research
Background Despite progress in stroke therapy (e.g., revascularisation interventions by thrombolysis and/or thrombectomy, organised stroke care), many stroke survivors will have impairment of neurological function.
Christopher Li Hsian Chen, Jia Hui Chai, Yogesh Mahadev Pokharkar, Narayanaswamy Venketasubramanian   +3 more
doaj   +4 more sources

Safety and Use of MLC601/MLC901 (NeuroAiD^TM) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry [PDF]

Brain Sciences, 2020
Background: MLC601/MLC901 (NeuroAiD™) is a combination of natural products shown to be safe and to aid neurological recovery after brain injuries, especially ischemic stroke. Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH)
Ramesh Kumar, Azizi Abu Bakar, Jegan Thanabalan, Sanmugarajah Paramasvaran, Charng Jeng Toh, Ainul Jaffar, Farizal Fadzil, Palaniandy Kamalanathan, Bee Hong Soon, Narayanaswamy Venketasubramanian   +9 more
doaj   +5 more sources

The Efficacy and Safety of Ischemic Stroke Therapies: An Umbrella Review [PDF]

Frontiers in Pharmacology, 2022
Background: Ischemic stroke is a leading cause of morbidity and mortality in neurological diseases. Numerous studies have evaluated the efficacy and safety of ischemic stroke therapies, but clinical data were largely inconsistent.
Yongbiao Li, Ruyi Cui, Fangcheng Fan, Yangyang Lu, Yangwen Ai, Hua Liu, Shaobao Liu, Yang Du, Zhiping Qin, Wenjing Sun, Qianqian Yu, Qingshan Liu, Yong Cheng, Yong Cheng   +13 more
doaj   +2 more sources

NeuroAid II (MLC901) in Haemorrhagic Stroke [PDF]

Case Reports in Neurology, 2020
Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke.
Chai-Hoon Nowel Tan, David Choy, Narayanaswamy Venketasubramanian   +2 more
doaj   +2 more sources

Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] [PDF]

F1000Research
Introduction NeuroAiD, also known as MLC601 or MLC901, is a Chinese herbal combination used worldwide for stroke treatment. It contains herbal components and five hewan components.
Dwi Arwandi Yogi Saputra, Tirta Darmawan Susanto, ARMAN YURISALDI SALEH, Riezky Valentina   +3 more
doaj   +2 more sources

Phase II randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of MLC1501 in patients with stroke: the MLC1501 study Assessing Efficacy in post-STrOke Subjects with mOtor deficits (MAESTOSO) study protocol [PDF]

Stroke and Vascular Neurology
Background MLC1501, consisting of four herbs, that is, Radix Astragali, Radix Angelicae sinensis, Rhizoma Chuanxiong, Radix Polygalae, has the same pharmacological properties as its precursors MLC601 and MLC901 which contain extracts of nine herbs and ...
Narayanaswamy Venketasubramanian, Deidre Anne De Silva, Christopher P L H Chen, Cyrus G Escabillas, John Harold Hiyadan, Johnny K Lokin, Romulo U Esagunde, Joel M Advincula, Christian Oliver C Co, Maria Epifania V Collantes, Annabelle Y Lao, Yeow-Hoay Koh, Carol Huilian Tham   +12 more
doaj   +2 more sources